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Platinum drugs are animportantclassofcancer chemotherapeutics.However,the useofthese drugs is limited by the development
of resistance during treatment with decreased accumulation being a commonmechanism. Both Cu transporters CTR1 and CTR2
inﬂuencetheuptakeandcytotoxicityofcisplatin.AlthoughitisstructurallysimilartoCTR1,CTR2 functionsinamanneropposite
tothat ofCTR1 withrespect to Pt drug uptake. Whereas knockoutof CTR1 reduces Pt drug uptake, knockdownofCTR2 enhances
cisplatin uptake and cytotoxicity. CTR2 is subject to transcriptional and posttranscriptional regulation by both Cu and cisplatin;
this regulation is partly dependent on the Cu chaperone ATOX1. Insight into the mechanisms by which CTR1 and CTR2 regulate
sensitivity to the Pt-containing drugs has served as the basis for novel pharmacologic strategies for improving their eﬃcacy.
1.Introduction
Platinum- (Pt-) based chemotherapeutic agents have been
utilized in the treatment malignancies since their ﬁrst
approval in the 1970s. Cisplatin, carboplatin, and oxaliplatin
a r et h et h r e em o s tc o m m o n l yu s e dP td r u g si nt h eU S Aa n d
are an essential part of the standard of care for lung, ovarian,
colorectal, testicular, bladder, and head and neck cancer as
well as other malignancies. Unfortunately the use of these
compoundsislimitedbybothacuteandcumulativetoxicities
as well as the development of resistance. The Pt-containing
drugs are believed to function in vivo by forming DNA
adductsthat lead to apoptosis. The mechanisms that account
for primary or acquired resistance to the Pt-containing
drugs continue to be the subject of intense study given the
clinical utility of these compounds. Resistance appears to be
multifactorial, and diﬀerences in DNA repair, detoxiﬁcation,
and drug accumulation have all been implicated [1, 2].
Decreased accumulation is one of the most commonly
observed features observed in resistant tumor cells both
in vitro and in vivo, and there are now multiple lines of
evidenceindicating that proteins involved in Cu homeostasis
are responsible for the import, intracellular distribution,
and export of the various Pt agents [1]. This short paper
will focus on recent developments in understanding how
the cellular pharmacology of the Pt-containing drugs is
inﬂuenced by proteins belonging to the Cu homeostasis
systemwith anemphasisontheCutransporter (CTR)family
and Cu transporter 2 (CTR2) in particular.
2.Overviewof CuHomeostasis
Cu is essential for the functioning of multiple cellular
enzymes including superoxide dismutase, cytochrome c
oxidase, lysyl oxidase, and dopamine β-hydrolase [3, 4].
These enzymes are required for crucial cellular processes
such as electron transport and detoxiﬁcation of reactive
oxygen species. The reactions mediated by these enzymes
involve the interconversion of Cu between two diﬀerent
oxidation states, Cu(I) and Cu(II). However, the ability
of Cu to undergo these redox reactions under physiologic
conditions makes it extremely toxic if left free within the cell.
For this reason, cells have developed a complex system of Cu
transportersandchaper onesthatbindC uandpr otectitfr om
oxidation such that there is essentially no free intracellular
Cu (less than 10−18 M). The components of the Cu transport
systems are highly conserved in biological organisms from
bacteria to humans, a feature that further highlights the
importance of this system.2 Metal-Based Drugs
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Figure 1: Schematic diagram of Cu homeostasis.
A common characteristic of Cu transport proteins
and chaperones is the presence of methionine, histidine,
or cysteine-rich motifs capable of chelating Cu. Cu and
other metal ions bind to these motifs through electrostatic
interactions which allow the transfer of a metal ligand either
from one domain to another of a single protein, or from
one protein to another, via transchelation reactions. Inﬂux
transporters are found in the plasma membrane that deliver
CutocytoplasmicCuchaperones that,inturn,transfer Cu to
either other Cu chaperones, Cu requiring enzymes, or other
transporters that concentrate it into the trans-Golgi network
and the secretory pathway.
Extracellular Cu(II) bound to ceruloplasmin is believed
to be converted to Cu(I) by cell surface reductases homolo-
goustoyeast FRE1and FRE2.Cuthenenters thecell as Cu(I)
in a non-energy-dependent process through a pore created
by a homotrimer of the high aﬃnity transporter CTR1
[5–7].Mammalian cellsalsoexpressasecondCutransporter,
CTR2, that has lower aﬃnity for Cu. It may also inﬂux Cu
across the plasma membrane [8], although studies in yeast
suggest its primary role is to export Cu from the vacuole
which serves as a Cu storage site [9, 10]. After entry into the
cell,CuispassedtothechaperonesATOX1,COX17,andCCS
eachofwhich thentransfers Cutoaspeciﬁc enzyme complex
(Figure 1). COX17 delivers Cu via additional chaperones to
cytochrome c oxidase whereas CCS delivers it to superoxide
dismutase. ATOX1 transfers Cu to the P-type ATPases
ATP7A and ATP7B which concentrate Cu into the trans-
Golgi for incorporation into ceruloplasmin and other Cu
containing proteins present in the secretory pathway. ATOX1
has recently also been shown to function as a Cu-sensitive
transcription factor [11]. In the setting of excess levels of Cu,
delivery of Cu to ATP7A and ATP7B triggers their traﬃcking
to the plasma membrane or vesicular structures near the
cell surface from which Cu is eventually exported [12–14].
Cu can also form complexes with glutathione from which
it is delivered to metallothionein II. Recent work by Banci
et al. [15] showed that the individual aﬃnities of the various
Cu containing chaperones and enzymes are such that they
provide a gradient that can drive Cu from the lower aﬃnity
chaperones and storage sites to the higher aﬃnity enzymes.
3.CharacteristicsofCTR1
CTR1 was ﬁrst identiﬁed in yeast as necessary for high
aﬃnity Cu import in the mid-1990s [5]. It is a highly
conserved protein as demonstrated by the fact that both
human and mouse CTR1 can rescue the growth defect
produced by knocking out CTR1 in S. cerevisiae [6, 16].
Human CTR1 contains 190 amino acids organized into
three transmembrane domains, an N-terminal extracellu-
lar domain rich in methionines and histidines, a large
intracellular loop, and a short intracellular C-terminal tail
(Figure 2(a)). Conserved methionine-containing motifs and
individual methionines, histidines, and cysteines essential
to Cu transporter function are found within the extracel-
lular domain, within the second and third transmembraneMetal-Based Drugs 3
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Figure 2: Schematic diagram of hCTR1 and hCTR2 showingmembrane topology and sequence. Important methionine residues within the
metal binding sequences and transmembrane regions are shown as darkened residues. The asterisk denotes other amino acids (H139 and
C189) important for Cu transport.
domains, as well as in the C-terminal tail. CTR1 forms a
homotrimer inthemembrane, and structural studiessuggest
that it assembles into an inverted cone-shaped pore through
which Cu(I)istransmitted fromonesideofthemembraneto
the other [17]. Recent computational studies provide further
support for the importance of several of these conserved
residues in transporter function, particularly within the
second transmembrane domain [18].4 Metal-Based Drugs
4.RegulationofPt Drug Cytotoxicityby CTR1
The Cu inﬂux and eﬄux transport proteins were ﬁrst linked
to the import of the Pt-containing drugs when it was noted
that cells selected for resistance to cisplatin were cross-
resistant to various other metals including Cu [19–23]. Cells
selected for resistance to Cu were found to be cross-resistant
to cisplatin and vice versa. Currently there is evidence that
changes in the expression of inﬂux transporters CTR1 and
C T R 2 ,t h ec h a p e r o n eA T O X 1 ,a n dt h ee ﬄux transporters
ATP7A and ATP7B alter sensitivity to the cytotoxic eﬀect
of the Pt-containing drugs [21, 24–26]. All these proteins
contain metal binding motifs which, in addition to binding
Cu, are likely to interact with the Pt drugs as evidenced
by the results of crystallographic and mass spectrometry
experiments [27–29].
The evidence that CTR1 functions as an importer for
the Pt-containing drugs has been reviewed recently [30], and
only the keypoints will be summarized here. CTR1-deﬁcient
yeast were noted to be resistant to both Cu and cisplatin
due to impaired uptake [24, 31], and subsequent studies in
mouseembryoﬁbroblastsinwhich bothallelesofCTR1were
knockedoutdocumentedthatthe inﬂuxofallthree clinically
used Pt-containing drugs was impaired. The largest eﬀect of
CTR1 appears to be on initial inﬂux, although a recent study
also identiﬁedenhanced eﬄuxinCTR1−/− cells[25].Knock-
out ofCTR1 results in nearly complete resistance to the ther-
apeutic eﬀect of cisplatin when mouse embryo ﬁbroblasts
are grown as xenografts in nu/nu mice [26]. More recent
work has focusedon the mechanism by which CTR1imports
the Pt drugs. Current evidence suggests that the Cu atom is
passed through the pore formed by the CTR1 trimer. Key to
this function is the conserved 40MMMMPM45 motif located
proximaltothestart oftheﬁrst transmembrane domain,and
methionines M150 and M154 in the second transmembrane
domain, both of which are required for optimal Cu uptake.
When assembled as a trimer, these residues appear to form
rings of methionines which line the channel and mediate the
passage of Cu through a series of transchelation reactions.
The conserved cysteine in the C terminus (C189) may also
play a role in Cu transport as there is evidence that it binds
Cuandmayserveaspartofagatingmechanism forthechan-
nel [32].The selectivity ofCTR1forCu(I)ratherthanCu(II)
may result from diﬀerences in their coordination chemistry
and the strength of the bond formed with the methionines.
The stronger bond formed by Cu(II) may limit the ability to
undergothetranschelation reactions proposedtobeessential
for uptake. In support of this, it has been recently reported
that silver, whose aﬃnity for the sulfur of methionine is
similar to that of Cu(I), is transported by CTR1 [33].
The details of how the Pt drugs pass through the CTR1
pore are still lacking. Although the Pt-containing drugs are
signiﬁcantly larger in size than Cu, it is possible that trimeric
CTR1 is quite expandable and may be able to accommodate
thesemoleculesastheypass through.Recentcomputermod-
eling studies of the transmembrane helices predict that these
structures are quite dynamic, with some critical portions,
such as the transmembrane methionines at 150 and 154 in
the second transmembrane domain, serving as hinges for the
overall structure [18]. The relative stability of these “hinge”
methioninesmakethemapotentialbottleneckinthepassage
of a Cu atom through the pore and may in fact be essential
to how the cell controls Cu inﬂux. The aﬃnity of cisplatin
for the sulfur of methionine is similar to that of Cu(I), and
it has been theorized that it may pass through the trimer
via a series of transchelation reactions in a manner similar
to Cu [30]. However, two recent studies noted that cisplatin
reacts with methionine-containing sequences quite slowly
relative to its rate of cellular uptake and that both ammine
ligands are lost when cisplatin reacts with either ATOX1
or a peptide containing a methionine motif similar to that
found in the N-terminal domain of CTR1 [27, 29]. Since the
ammine ligands are present in the DNA adducts formed by
cisplatin and reacquisition of ammine ligands intracellularly
once lost is unlikely, if cisplatin is passing through the pore
it must do so in a manner that retains the ammines. Other
recent work indicates that there are substantial diﬀerences
in the way in which CTR1 transports Cu and cisplatin. For
example, conversion of the methionines at 150 and 154 to
isoleucines, while impeding Cu transport, actually increases
the uptake of cisplatin [34]. The CTR1 conformation that
best accommodates Cu may not be the best for cisplatin.
H139isknownto aﬀecttheabilitytotransport Cu.Mutation
of this residue impairs Cu uptake, and the computational
model suggests that the interaction of this residue with
G84 stabilizes an active Cu transporting conformation. With
regards to cisplatin, mutationofH139resulted in an increase
in cisplatin transport suggesting that this lifts restrictions
that allow the pore to adopt conformations more amenable
to cisplatin transport but which are detrimental to Cu ﬂux.
The role of the most N-terminal histidine and methion-
ine motifs in CTR1 with respect to the transport of either Cu
or the Pt-containing drugs has not been well deﬁned. When
Cu is abundant, these motifs are not required for Cu uptake
although they enhance transport when Cu is scarce [35–
38]. The Pt-containing drugs are capable of interacting with
metal binding motifs such as those found in the N-terminal
region of CTR1, and deletion of the 40MMMMPM45 motif,
or of the entire ﬁrst 45 amino acids, impairs cisplatin uptake
[28, 39, 40]. Quite possibly these N-terminal motifs serve to
funnel Cu and cisplatin towards the transmembrane pore.
5.CharacteristicsofCTR2
yCTR2 was identiﬁed on the basis of its ability to rescue
the growth of S. cerevisiae that were Cu deﬁcient due
to defective yCTR1 and yCTR3, the normal high aﬃnity
membrane transporters in this organism [41]. Initially it
was thought that yCTR2 functioned as a low aﬃnity Cu
inﬂux transporter at the cell surface. Work by Portnoy et
al. [10] and Rees et al. [9] showed that in yeast yCTR2
was primarily localized to vacuolar membranes. Deletion
of the gene coding for yCTR2 increased the vacuolar Cu
level suggesting that yCTR2 functions to release vacuolar
stores of Cu when cytoplasmic Cu is low. Export of Cu from
these intracellular stores through yCTR2 was found to be
dependent on the vacuolar Cu reductase Fre6 that is likely
needed to convert vacuolar Cu(II) to Cu(I) permitting it toMetal-Based Drugs 5
betransported byyCTR2[42]. Fre1and 2at theyeast plasma
membrane serve a similar role in reducing Cu(II) to Cu(I)
prior to transport by yCTR1 [42]. However, a variant of
yCTR2 was found that mislocalized to the cell surface. This
variant, identiﬁed as yCTR2-1, contained two mutations,
a tryptophan to arginine mutation at position 7 and a C
terminal truncation of the last 16 amino acids of yCTR2.
When thus localized to the plasma membrane yCTR2-1 was
capable of importing extracellular Cu and of reversing the
growth impairment of yeast deﬁcient in both yCTR1 and
yCTR3 [9, 42].
In mammalian cells the majority of CTR2 is localized to
the late endosome and lysosome compartments with little
present at the cell surface; there may be some colocalization
with CTR1 at intracellular sites [43, 44]. This would suggest
that, similar to yCTR2, mammalian CTR2 functions to
release intracellular stores of Cu as these structures are
similarinfunctiontotheyeastvacuole.H owever ,thereisalso
evidence in mammalian systems that CTR2 can function as
a Cu inﬂux transporter. Van Den Berghe et al. [43]f o u n d
that overexpression of CTR2 in HEK 293 cells increased the
expression of a reporter sensitive to intracellular Cu levels.
Bertinato etal. [8]also found thatforced expression ofCTR2
mediated Cu import in the presence of high concentrations
of extracellular Cu and that siRNA-mediated knockdown
of CTR2 reduced Cu uptake. The aﬃnity of CTR2 for Cu
calculated from these studies (Km ∼6–11μM) was lower
than that for CTR1 (Km ∼1.7μM) [8]. However, both of
these studiesutilized cellsin which CTR2was over-expressed
which may have resulted in abnormalities of distribution
with an unusual amount ofCTR2 directed to the cell surface.
In addition, these studies also used C-terminally tagged
f o r m so fC T R 2 ,a n dt h i sc o u l dh a v ei n t e r f e r e dw i t hn o r m a l
traﬃcking although no clear alteration in distribution was
noted. It is of interest that the C-terminal end of CTR2
contains a conserved double leucine which mediates the
endocytotic retrieval of many transmembrane proteins from
the plasma membrane. It has already been shown in yeast
that yCTR2-1 mutant which was missing the C-terminal
16 amino acids is mislocalized to the cell surface and can
mediate extracellular Cu transport, and it is possible that
similar phenomenon could have occurred in these studies.
No information is currently available on the ability of CTR2
toexportCufromtheendosomal/lysosomalcompartmentin
mammalian cells.
Given the paucity of studies on CTR2 to date, much
of the structure-function relationships in CTR2 must be
inferred from studies done on CTR1. CTR2 has signiﬁcant
structural homology to CTR1 although it only shares ∼41%
amino acid sequence homology. Similar to CTR1, CTR2
has an extracytoplasmic N-terminus, three transmembrane
domains, a large intracellular loop, and a short intracellular
C-terminus (Figure 2(b)). It also contains a conserved
1MXM3 motif within the N-terminus, approximately 23
residues from the ﬁrst transmembrane domain, as well
as conserved methionines in the second transmembrane
domain in the form of 111MXXXM115. However, it is missing
the more distal N-terminal metal binding domains and
the cysteine that is present in the penultimate position
in the C-terminal tail of CTR1. CTR2 forms oligomeric
complexes, and given the structural homology to CTR1,
it is presumed that CTR2 forms homotrimers which may
function as a channel [43]. Mutation of the extracellular N-
terminal methionines at residues 59 and 61, or the second
transmembrane M148 and M152 of yCTR2, resulted in
ap r o t e i nt h a tw a su n a b l et or e s c u et h eC ud e ﬁ c i e n c y
of a ΔCTR1 ΔCTR3 ΔCTR2 yeast strain, and this was
believed to be due to inability of the mutant yCTR2 to
transport Cu [9]. The equivalent methionine residues are
also known to be important in the Cu transport function
of CTR1 and strongly suggest that CTR2 is capable of
transporting Cu by a similar mechanism. Presumably the
rings of methionines formed when the trimeric complex is
assembled are involved in coordinating metal atoms as they
pass through the CTR2 pore. Further, the ability of yCTR2
mutants to transcomplement each other also supports the
supposition that CTR2 forms homo-oligomers, presumably
a trimer similar to CTR1 [9].
As in yeast, when the methionines in the 111MXXXM115
motif in the second transmembrane domain of mammalian
CTR2 were converted to 111IXXXI115 the ability to accu-
mulate Cu and activate a Cu-responsive promoter was
impaired [43]. No data are available on the importance of
the methionines in the extracellular N-terminus of CTR2
although inference from yeast and the conserved nature of
these residues would also suggest these are essential for Cu
transport as well. There are other residues within CTR2 that
are conserved across species that also diﬀer from CTR1,
such as the C-terminal double leucine, but the functional
signiﬁcance of these has not been investigated to date.
While CTR1 resides entirely outside the nucleus, CTR2
is found both in the endosomal/lysosomal compartment
and also within the nucleus in a punctuate distribution not
immediatelyrecognizableasbeingsimilartothatofanyother
nuclear protein as determined by immunocytochemical
staining and deconvoluting microscopy [45]. This ﬁnding
has been conﬁrmed by western blot analysis of isolated
nuclei. It is tempting to speculate that nuclear CTR2 is
involved in the regulation of nuclear Cu levels although it
is unlikely that nuclear CTR2 is associated with membranes
given its location and distribution within the nucleus, and
it thus seems doubtful that it is functioning as a metal
transporter at this site. CTR2 does not contain any obvious
nuclear localization signal or DNA binding motifs, and it
likely interacts with other proteins to reach the nucleus. Its
presence in the nucleus also begs the question of how a
transmembrane protein could be present in a soluble form.
However, the epidermal growth factor receptor (EGFR) and
CD44 provide precedent for the ﬁnding of transmembrane
proteins in the nucleus [46, 47].
6.RegulationofCuandPt Drug
Cytotoxicityby CTR2
Initial experiments on mammalian CTR2 showed that it
was capable of importing Cu into the cell under conditions
of excess extracellular Cu; little eﬀect was observed at6 Metal-Based Drugs
low Cu concentration (∼2μM) [8, 43]. These experiments
used systems in which CTR2 was forcibly over-expressed
and the ability of CTR2 to mediate Cu import has not
been consistently reported. More recent work showed that
when CTR2 was stably knocked down there was a modest
increase in Cu uptake but little eﬀect on Cu toxicity [25].
This eﬀect was even less apparent in CTR1−/− cells, and
CTR2 knockdown was associated with little eﬀect on Cu
cytotoxicityregardless ofCTR1expressionfurthersuggesting
that CTR2 plays little role in the import of extracellular Cu.
Given the structural similarities between CTR1 and
CTR2, studies were undertaken to determine whether CTR2
played any role in transport of the Pt-containing drugs.
Experiments performed in mouse embryonic ﬁbroblasts
showed that knockdown of CTR2 had a large eﬀect on
the accumulation of both cisplatin and carboplatin [25].
However, instead of limiting import, knockdown of CTR2
increased the uptake of both cisplatin and carboplatin by
a factor of 2-3-fold, an eﬀect opposite to that of knocking
out CTR1. This increase in Pt drug uptake translated to
an increase in formation of Pt-DNA adducts and increased
cytotoxicity. The increased uptake was found to be due to
enhancedinitialinﬂuxratherthanan eﬀectoneﬄuxandwas
independent of CTR1 as a similar increase occurred when
CTR2 was knocked down in CTR1−/− cells. No change was
detected in the concentration of Pt in the microvesicular
fraction, although as whole cell Pt increased a smaller
fraction of total intracellular Pt was found in this fraction
suggesting impaired loading of Pt into this compartment.
Thus, it appears that CTR1 and CTR2 have opposite eﬀects
on Pt drug uptake. As of yet, the mechanism by which CTR2
controls Pt drug uptake is still unclear. Whether the eﬀect of
C T R 2i n v o l v e sd i r e c tt r a n s p o r to ri ss e c o n d a r yt oe ﬀects on
other import pathways is unknown. However, the fact that
theknockdownofCTR2causes a similar increase in cisplatin
uptake in the presence or absence of CTR1 suggests that it is
involved in a non-CTR1 dependent mechanism of uptake.
7.RegulationofCTR2Expressionby
CuandCisplatin
The level of CTR1 is altered by exposure to Cu or cisplatin,
and this appears to be true for CTR2 as well. Exposure of
many types of cells to high concentrations of Cu, or low
concentrations of cisplatin, results in the downregulation
of CTR1 by a process that involves macropinocytosis,
ubiquitination, and proteasomal degradation [48–50]. This
has been interpreted as a mechanism that helps limit the
toxicity of high extracellular levels of Cu. CTR2 expression
is also aﬀe c t e db ye x p o s u r et oC ua n dc i s p l a t i nb u tt h e r e
are discrepancies between various systems in which this
has been examined. In the green alga Chlamydomonas
reinhardtii and the fungus Colletotrichum gloeosporioides
CTR2 expression was found to decrease in the presence
of high extracellular levels of Cu [51, 52]. In contrast, in
mammalian cells exposure to either Cu or cisplatin resulted
in an increase in CTR2 mRNA and protein levels [45].
The diﬀerence between the eﬀect of Cu in mammalian
cells versus that in algae and fungus may reﬂect species
diﬀerences and variation in nomenclature. It is notable that
CTR2 in Colletotrichum is actually more closely related to
humanCTR1when examined byBLASTsequencealignment
consistent with this contention and even contains additional
N-terminal extracellular metal binding sequences similar to
hCTR1 that are lacking in hCTR2. The protein named CTR2
in Chlamydomonas, while also mediating Cu transport, is
several times larger than CTR2 in mammalian cells being
over 800 amino acids in length. It also contains diﬀerent
types of metal binding sequences and appears to have been
named “CTR2” based more on the fact that it was the
second CTR family protein described in that species [51]
rather than on the basis of its similarity to CTR2 in other
species.
The regulation of CTR2 expression occurs at both
transcriptional andposttranscriptional levelsasmRNAlevels
as well as protein half-life are aﬀected. Exposure to 30μM
cisplatinforonehourincreased boththemRNAlevelandthe
proteinlevelby∼1.5-foldwhereastreatmentwith100μMCu
increased both mRNA and protein levels by ∼3-4-fold at 1
hour [45]. This increase in protein level was accompanied by
an increase in protein half-life by 3.1-fold to 43.6 minutes
in cisplatin-treated cells and by 1.6-fold to 22.7 minutes
in Cu-pretreated cells. This posttranscriptional regulation is
dependent on the Cu chaperone ATOX1 as ATOX1−/− cells
areunabletoup-ordown-regulate CTR2followingexposure
to Cu, cisplatin, or the Cu chelating agent bathocuproine
disulphonate (BCS). Although ATOX1 has been shown to
function in the nucleus to regulate transcription [11]a n d
there are some putative ATOX1 binding sites in the CTR2
promoter, the regulation of CTR2 by ATOX1 appears to be
at the posttranscriptional level as mRNA levels still increase
or decrease in response to drug exposure in a manner similar
to that in ATOX1+/+ cells [45]. The decreased CTR2 protein
half-life observed following Cu starvation is at least in part
due to increased proteasomal degradation as the proteasome
inhibitor bortezomib can block this eﬀect; interestingly,
bortezomib also blocks the degradation of CTR1 induced
by cisplatin exposure [50]. The details of the mechanism
by which ATOX1 controls the Cu- or cisplatin-induced
regulation of eitherCTR1 orCTR2 remain to be worked out.
8.Discussion
Many of the proteins involved in Cu homeostasis inﬂuence
the uptake and cytotoxicity of the Pt-containing drugs [1,
21, 53], and cisplatin has been shown to interact with
several of these including the eﬄux pump ATP7B [54].
The current model of Pt drug uptake suggests that Cu
transporters and chaperones mediate drug uptake and eﬄux
in a manner similar to Cu [30]. The observation that
reduction in the expression of CTR1 and CTR2 has opposite
eﬀects on the cytotoxicity of Cu and cisplatin, and that
both Cu and cisplatin regulate CTR1 and CTR2 in opposite
directions, suggests that these two transporters function
quite diﬀerently in the cell and do not simply participate in
redundant pathways of Cu inﬂux. Whereas CTR1 mediatesMetal-Based Drugs 7
accumulation of the Pt-containing drugs, CTR2 appears to
limit their inﬂux in mouse embryo ﬁbroblasts.
The evidence that CTR1 controls uptake of the Pt drugs
is now quite strong and has been conﬁrmed by multiple
laboratories [24, 31, 55–58]. However, the evidence that
CTR2 regulates Pt drug accumulation has come from just
one laboratory and requires veriﬁcation. Although a model
of how the Pt drugs might pass through the pore formed
by CTR1 via a series of transchelation reactions has been
proposed [59], there remains the possibility that CTR1
delivers cisplatin into the cell also by chelating it via the N-
terminal methionines followed by endocytosis or that CTR1
regulates a separate Pt drug inﬂux mechanism. This diﬀerent
mechanism could be dependent on Cu, and the observed
decrease in cisplatin uptake in CTR1 mutants could be due
toaderangementinCumetabolism.Notunexpectedly,given
the diﬀerences in their structure, there is now evidence for
substantial diﬀerences in the details of how Cu and cisplatin
interact with CTR1 [34, 40, 60].
Based on its structural similarity to CTR1, its ability to
modulate Cu inﬂux when situated in the plasma membrane,
and its ability to export Cu from the yeast vacuole, it is very
likely that CTR2 also forms a pore in cellular membranes
through which Cu passes. CTR2 limits cisplatin uptake and
this appears to be the result of reduced initial inﬂux rather
than enhanced eﬄux. This eﬀect of CTR2 is independent
of CTR1 as knockdown of CTR2 produced the same eﬀect
in both CTR1+/+ and CTR1−/− cells. This argues against the
idea that CTR1 and CTR2 act in series to mediate cisplatin
accumulation. Based on its role in S. cerevisiae one might
imagine that the primary function of CTR2 is to shuttle
Cu and the Pt drugs between intracellular compartments.
However,theﬁndingthatPtaccumulationinthemicrosomal
fractionremained unchangedincellsinwhich theexpression
of CTR2 was knocked down argues against a role for CTR2
in either sequestering or eﬄuxing cisplatin from vesicles
as this would have been expected to alter the microsomal
content of Pt which was not observed [25]. Thus, how CTR1
enhances and CTR2 limits Pt drug uptakeremains enigmatic
at present.
Given that CTR2 has such a large eﬀect on Pt drug
uptake and cytotoxicity, the pharmaceutical regulation of
CTR2 expression may allow the eﬃcacy of the Pt drugs to
be manipulated to enhance selectivity. One potential way
in which this might be achieved is through the use of
Cu chelators to decrease the level of CTR2 expression and
thus increase Pt drug uptake. Indeed, this very method has
recently been shown to improve cisplatin eﬃcacy in an in
vivo mouse cervical cancer model in which pretreatment
with the Cu chelator tetrathiomolybdate was shown to
increase the uptake of cisplatin and tumor killing [61].
Regardless of the mechanisms by which CTR1 and CTR2
transport the Pt drugs, there is little doubt that they have
relatively large eﬀects on the cytotoxicity of cisplatin both in
vitro and in vivo. A potential clinical application has already
emerged from studies of how the Cu homeostasis proteins
inﬂuence the cellular pharmacology of the Pt drugs. A
clinicaltrial ofintraperitonealpretreatment withbortezomib
prior to the intraperitoneal administration of carboplatin
in patients with ovarian cancer, directed at preventing
carboplatin-induced CTR1 downregulation, has just been
opened. A more detailed understanding of the mechanism
by which Cu homeostasis transporters and chaperones inﬂu-
ence the cytotoxicityof the Pt drugs has a high probability of
resulting in further improvement of the therapeutic index of
this important class of chemotherapeutics.
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